Table 1. Urine and plasma cell-free DNA BRAF VGOOE mutations.
Patient# | Age at diagnosis | Gender | Involvement | Urine BRAF VGOOE/WT | Plasma BRAF VGOOE/WT | Patient Tissue BRAFstatus |
---|---|---|---|---|---|---|
1 | 59 | Male | CNS, cardiac, bones, renal | V600E (22.590%) | V600E (8.598%) | V600E |
2* | 43 | Male | CNS, bones, renal | V600E (0.311%) | V600E (1.522%) | V600E |
3 | 26 | Male | Skin | Wild-type (0.010%) | Wild-type (0.063%) | Wild-type |
4 | 71 | Female | Bones, lymph nodes | V600E (0.159%) | Wild-type (0.047%) | Unknown** |
5 | 43 | Female | CNS, bones | V600E (4.940%) | V600E (0.261%) | Unknown** |
6 | 49 | Male | CNS, cardiac, omentum, retroperitoneum | Wild-type indeterminate (0.079%) | Wild-type (0.048%) | Unknown** |
CNS; central nervous system
Urine and plasma collected on different dates
lnsuficient tissue for molecular analysis